(Q42853336)

8 November 2017

title

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients (English)

1 reference

8 November 2017

1 reference

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20960678

6 August 2024

8

Christine Katlama

0 references

Geneviève Chêne

4

object named as

Geneviève Chêne

1 reference

8 November 2017

9

Diane Descamps

1 reference

8 November 2017

2

Yazdan Yazdanpanah

1 reference

8 November 2017

10

Jean-Michel Molina

1 reference

8 November 2017

12

Anne-Marie Taburet

1 reference

8 November 2017

1

Aurélie Barrail-Tran

1 reference

8 November 2017

6

Christophe Piketty

1 reference

8 November 2017

11

Catherine Fagard

1 reference

8 November 2017

Lauriane Goldwirt

3

1 reference

8 November 2017

Céline Colin

5

1 reference

8 November 2017

Diane Bollens

7

1 reference

8 November 2017

ANRS 139 study group

13

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

8 November 2017

23 October 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20960678

6 August 2024

1 reference

8 November 2017

volume

24

1 reference

8 November 2017

issue

16

1 reference

8 November 2017

page(s)

2581-2583

1 reference

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

8 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection

6 August 2024

2

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

6 August 2024

3

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

6 August 2024

4

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Clinical pharmacokinetics and pharmacodynamics of etravirine

6 August 2024

5

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

6 August 2024

7

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Lack of a significant drug interaction between raltegravir and tenofovir.

6 August 2024

8

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases

6 August 2024

9

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

6 August 2024

10

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

6 August 2024

11

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833D89FA

6 August 2024

Identifiers

1 reference

8 November 2017

1 reference